Bissan Al-Lazikani
#108,266
Most Influential Person Now
Researcher
Bissan Al-Lazikani's AcademicInfluence.com Rankings
Bissan Al-Lazikanicomputer-science Degrees
Computer Science
#10455
World Rank
#10982
Historical Rank
Database
#7937
World Rank
#8264
Historical Rank
Bissan Al-Lazikanibiology Degrees
Biology
#8546
World Rank
#11642
Historical Rank
Bioinformatics
#189
World Rank
#191
Historical Rank
Computational Biology
#340
World Rank
#341
Historical Rank
Download Badge
Computer Science Biology
Bissan Al-Lazikani's Degrees
- Masters Bioinformatics University of Manchester
- Bachelors Computer Science University of Manchester
Similar Degrees You Can Earn
Why Is Bissan Al-Lazikani Influential?
(Suggest an Edit or Addition)According to Wikipedia, Professor Bissan Al-Lazikani PhD FRSB MBCS is a data scientist and drug discoverer. She applies computational techniques to help solve critical bottlenecks in cancer drug discovery and development. Since 2021 she has been professor of genomic medicine at The University of Texas MD Anderson Cancer Center.
Bissan Al-Lazikani's Published Works
Published Works
- How many drug targets are there? (2006) (3268)
- ChEMBL: a large-scale bioactivity database for drug discovery (2011) (2858)
- A comprehensive map of molecular drug targets (2016) (1330)
- The genome of the blood fluke Schistosoma mansoni (2009) (992)
- Combinatorial drug therapy for cancer in the post-genomic era (2012) (822)
- Standard conformations for the canonical structures of immunoglobulins. (1997) (658)
- Defective acute inflammation in Crohn's disease: a clinical investigation (2006) (409)
- Therapeutic opportunities within the DNA damage response (2015) (394)
- Genomic-scale prioritization of drug targets: the TDR Targets database (2008) (288)
- Protein structure prediction. (2001) (240)
- Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance (2012) (233)
- Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets (2018) (169)
- canSAR: updated cancer research and drug discovery knowledgebase (2013) (118)
- Objective assessment of cancer genes for drug discovery (2012) (118)
- Drug discovery in advanced prostate cancer: translating biology into therapy (2016) (106)
- Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. (2010) (102)
- Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines (2016) (92)
- JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells (2013) (86)
- Minimum information about a bioactive entity (MIABE) (2011) (84)
- canSAR: an integrated cancer public translational research and drug discovery resource (2011) (70)
- Effective function annotation through catalytic residue conservation. (2005) (68)
- canSAR: update to the cancer translational research and drug discovery knowledgebase (2018) (64)
- PDBe-KB: a community-driven resource for structural and functional annotations (2019) (63)
- A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma (2011) (59)
- Objective, Quantitative, Data-Driven Assessment of Chemical Probes (2017) (59)
- The kinase polypharmacology landscape of clinical PARP inhibitors (2020) (59)
- Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. (2013) (59)
- Canonical structures for the hypervariable regions of T cell αβ receptors 1 1 Edited by J. M. Thornton (2000) (55)
- Polypharmacology in Precision Oncology: Current Applications and Future Prospects (2016) (55)
- Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains. (2003) (52)
- canSAR: an updated cancer research and drug discovery knowledgebase (2015) (49)
- Drugging cancer genomes (2013) (48)
- Oral Bioavailability, (46)
- SCOPEC: a database of protein catalytic domains (2004) (40)
- Collation and data-mining of literature bioactivity data for drug discovery. (2011) (39)
- Distinctive Behaviors of Druggable Proteins in Cellular Networks (2015) (39)
- The complement of enzymatic sets in different species. (2005) (39)
- A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations (2019) (35)
- canSAR: update to the cancer translational research and drug discovery knowledgebase (2020) (28)
- Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer (2017) (22)
- PDBe-KB: collaboratively defining the biological context of structural data (2021) (22)
- Canonical structures for the hypervariable regions of T cell alphabeta receptors. (2000) (20)
- Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases (2019) (19)
- Public resources for chemical probes: the journey so far and the road ahead. (2019) (17)
- Transforming cancer drug discovery with Big Data and AI (2019) (16)
- Personalized medicine: patient-predictive panel power. (2012) (15)
- SAR (Structure–Activity Relationship) (2014) (13)
- Target 2035 – update on the quest for a probe for every protein (2021) (13)
- A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. (2013) (13)
- Rational design of non-resistant targeted cancer therapies (2017) (12)
- Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers (2019) (12)
- JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer (2021) (12)
- Blocking the survival of the nastiest by HSP90 inhibition (2016) (10)
- QSAR (Quantitative Structure Activity Relationship) (2004) (8)
- Unpicking the combination lock for mutant BRAF and RAS melanomas. (2013) (8)
- The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use (2022) (7)
- The Molecular Basis of Predicting Druggability (2008) (7)
- SiGNet: A signaling network data simulator to enable signaling network inference (2017) (6)
- Chapter 36. The Molecular Basis of Predicting Druggability (2008) (6)
- Tuning Local Hydration Enables a Deeper Understanding of Protein–Ligand Binding: The PP1-Src Kinase Case (2020) (5)
- Coronavirus canSAR – a Data-Driven, AI-Enabled, Drug Discovery Resource for the Research Community (2020) (4)
- Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches (2020) (4)
- Evolution of kinase polypharmacology across HSP90 drug discovery (2020) (4)
- The off-target kinase landscape of clinical PARP inhibitors (2019) (3)
- Genomics, bio specimens, and other biological data: Current status and future directions (2018) (3)
- Chemical Hashed Fingerprint (2014) (3)
- canSAR chemistry registration and standardization pipeline (2022) (2)
- Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes (2022) (2)
- Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. (2016) (2)
- Protein structure prediction. (2008) (2)
- OC-0061: Big-RT: Big Data analysis to identify predictors of radiotherapy toxicity for personalised treatment (2018) (1)
- Leveraging Human Genetics to Guide Cancer Drug Development. (2018) (1)
- Abstract B096: canSAR, a cancer research and drug discovery knowledgebase (2018) (1)
- Rule of Five (Lipinski Rule of Five) (2014) (1)
- Abstract 2730: RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with HSP90 inhibition (2014) (1)
- New open drug activity data at EBI (2009) (1)
- KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies. (2018) (1)
- GPCR knowledgebase - from sequences to ligands. (2005) (0)
- LogP (ALogP, CLogP) (2014) (0)
- Compound Similarity and Similarity Searching (2014) (0)
- Abstract 4383: SOCRATES: integrating ex vivo and in silico analysis to identify optimal drug combinations for patients (2016) (0)
- EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM (2018) (0)
- Target in Renal Cell Carcinoma A HIF-Regulated VHL-PTP 1 B-Src Signaling Axis Identifies a Therapeutic (2011) (0)
- The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates (2022) (0)
- Failure of the acute inflammatory response in Crohn's disease: The influence of CARD15 (2004) (0)
- Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases (2020) (0)
- Targeting the BAG-1 family of co-chaperones in lethal prostate cancer (2022) (0)
- 2 . 2 Identifying catalytic domains in the PDB (2004) (0)
- Characterisation of the defect in acute inflammation in Crohn's disease and the influence of CARD15 (2004) (0)
- Abstract 3099:KRASand clinical context: Differential dynamic signaling output ofKRASmutant lung, colorectal and pancreatic cancer cell lines when exposed to targeted anticancer drugs (2016) (0)
- Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets (2018) (0)
- R-loop editing by DNA cytosine deaminase APOBEC3B determines the activity of estrogen receptor enhancers (2022) (0)
- Abstract 996: A translational phosphoproteomic approach to study differences inKRASsignaling in pancreatic, colorectal and lung cancers (2017) (0)
- canSAR: update to the cancer translational research and drug discovery knowledgebase (2022) (0)
- Abstract CN01-02: canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation. (2011) (0)
- Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group (2012) (0)
- The Chemical Probes Portal: an enhanced public resource providing expert advice on chemical tools for cancer research (2022) (0)
- Unravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials (2018) (0)
- Abstract 1821: Genome-wide genetic screens define the drug resistance landscape of BRAF mutant colon cancer (2018) (0)
- Abstract A024: Probe Miner: objective, quantitative, data-driven assessment of chemical probes for target validation (2018) (0)
- Abstract 4164: The druggable proteome: Identifying novel target families for cancer (2014) (0)
- Abstract A067: Targeting the bromodomain and extra-terminal (BET) family proteins and beyond in metastatic castration-resistant prostate cancer (mCRPC): Overcoming aberrant androgen receptor (AR) signaling (2018) (0)
- The kinase polypharmacology landscape of clinical PARP inhibitors (2019) (0)
- Abstract 776: Utilising genetic susceptibility and big data to inform novel cancer therapies (2018) (0)
- Druggable Genome (Druggable Proteome) (2014) (0)
- Chemogenomic assessment of SAR data from learned journals (2005) (0)
- Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen (2019) (0)
- Bemis and Murcko Framework (Murcko Framework) (2014) (0)
This paper list is powered by the following services:
Other Resources About Bissan Al-Lazikani
What Schools Are Affiliated With Bissan Al-Lazikani?
Bissan Al-Lazikani is affiliated with the following schools: